Skip to main content

Table 3 Treatment response in different populations

From: Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

  ITT population (N = 45) Evaluable population (N = 43) Estrogen receptor positive (N = 26) Her-2 positive (N = 5)
Tumor response     
CR, n (%) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
PR, n (%) 18 (40.0 %) 18 (41.9 %) 12 (46.2 %) 1 (20.0 %)
SD, n (%) 18 (40.0 %) 18 (41.9 %) 11 (42.3 %) 3 (60.0 %)
PD, n (%) 7 (15.6 %) 7 (16.3 %) 2 (7.7 %) 1 (20.0 %)
NE, n (%) 2 (4.4 %) 0 (0.0 %) 1 (3.8 %) 0 (0.0 %)
Disease control rate     
CR + PR + SD, n (%) 36 (80.0 %) 36 (83.7 %) 23 (88.5 %) 4 (80 %)
Objective response rate     
CR + PR, n (%) 18 (40.0 %) 18 (41.9 %) 12 (46.2 %) 1 (20.0 %)
  1. Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; NE: not evaluable